PhD, BSc (Hons)
Postdoctoral Research Scientist
I completed my PhD program at the University of Western Australia focusing on the development of antisense oligonucleotides to modulate splicing in disease models of Duchenne muscular dystrophy, in particular in canine and human cellular models.
I have been a Postdoctoral Research Scientist in the field of pre-clinical translational research for the past 11 years where my focus has been predominantly on development of antisense oligonucleotide therapeutics for neuromuscular diseases, in particular for Duchenne muscular dystrophy (DMD). In my current role, I am lead scientist and Project Manager in the group for a number of collaborative programs with pharmaceutical partners including Pfizer and Wave LifeSciences, focusing on pre-clinical development of novel therapeutic drugs for DMD.
Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics.
McClorey G. and Banerjee S., (2018), Biomedicines, 6
PROFILE OF CIRCADIANLY REGULATED METABOLIC GENES IN DYSTROPHIC HEART
Betts CA. et al, (2018), Heart, 104, A4 - A4
Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
Blain AM. et al, (2018), Plos one, 13
Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD)
Panzara M. et al, (2017), Journal of the neurological sciences, 381, 277 - 278
WVE-210201, an investigational stereopure oligonucleotide therapy for Duchenne muscular dystrophy, induces Exon 51 skipping and dystrophin protein restoration
Wood M. et al, (2017), Neuromuscular disorders, 27, S217 - S217